Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TPG Capital to acquire Axcan

TPG Capital will acquire Axcan (TSX:AXP; AXCA) for $23.35 per share, or about $1.3

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE